Ribavirin's Effectiveness Against Andes Virus Infection
Author Information
Author(s): David Safronetz, Elaine Haddock, Friederike Feldmann, Hideki Ebihara, Heinz Feldmann
Primary Institution: National Institute of Allergy and Infectious Diseases, National Institutes of Health
Hypothesis
Does ribavirin effectively inhibit Andes virus replication in vitro and in vivo?
Conclusion
Ribavirin is highly effective in preventing lethal hantavirus pulmonary syndrome in hamsters when administered early after infection.
Supporting Evidence
- Ribavirin treatment resulted in dose-dependent reductions in viral RNA and protein.
- 100% protection was observed in hamsters treated with ribavirin starting from day 1 post-infection.
- Significant reductions in ANDV RNA were noted in lung and liver tissues of treated hamsters.
- Ribavirin remained effective even when administered up to three days post-infection.
Takeaway
Ribavirin can help sick hamsters recover from a dangerous virus called Andes virus, especially if given soon after they get sick.
Methodology
The study involved in vitro tests on Vero E6 cells and in vivo tests on hamsters infected with Andes virus, assessing ribavirin's antiviral effects.
Potential Biases
Potential bias in animal model applicability to human disease.
Limitations
The study's findings may not directly translate to human cases due to differences in immune response and disease progression.
Participant Demographics
Syrian hamsters, female, aged 4–6 weeks.
Statistical Information
P-Value
p=0.0022
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website